Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1801 Target Snapshot

Plasminogen · SINGLE PROTEIN · Homo sapiens

2,020Compounds
473Assays
9Approved Drugs
1,899.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Plasminogen shows approved-linked disease relevance led by hemorrhage. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P00747. Start with hemorrhage, then reuse UniProt P00747 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hemorrhage, then reuse UniProt P00747 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
hemorrhage

Plasminogen shows approved-linked disease relevance led by hemorrhage. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with hemorrhage because it currently carries approved-linked support. Linked drugs include AMINOCAPROIC ACID, APROTININ, TRANEXAMIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Plasminogen as ChEMBL target CHEMBL1801, mapped to UniProt P00747. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Plasminogen
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1801
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P00747
Plasminogen
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Plasminogen is the right protein anchor across sources, using UniProt P00747 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hemorrhage is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPlasminogen
UniProt AccessionP00747
Component TypeProtein
Sequence Length810 aa

Plasminogen

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Plasminogen, mapped to UniProt P00747. Sequence length is 810 aa.

Mapped IDP00747
Review namePlasminogen
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Plasminogen shows approved-linked disease relevance led by hemorrhage. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hemorrhage
3 linked drugs · 3 direct · 3 efficacy
Linked drugAMINOCAPROIC ACID
Linked drugAPROTININ
Linked drugTRANEXAMIC ACID
Approved-linked Approved
Recurrent thrombophlebitis
3 linked drugs · 3 direct · 3 efficacy
Linked drugANISTREPLASE
Linked drugDEFIBROTIDE
Linked drugSTREPTOKINASE
Approved-linked Approved
hepatic veno-occlusive disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugDEFIBROTIDE
Linked drugDEFIBROTIDE SODIUM
Approved-linked Approved
hemophilia A
1 linked drug · 1 direct · 1 efficacy
Linked drugTRANEXAMIC ACID
Approved-linked Approved
Menorrhagia
1 linked drug · 1 direct · 1 efficacy
Linked drugTRANEXAMIC ACID
Late clinical Phase III
coronary artery disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugSTREPTOKINASE
Linked drugTRANEXAMIC ACID
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with hemorrhage because it currently carries approved-linked support. Linked drugs include AMINOCAPROIC ACID, APROTININ, TRANEXAMIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehemorrhage
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

9
Approved
6
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC50801.0
KI1,078.0
EC503.0
KD17.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2448441 11.0 Ki 0.01 Preclinical
CHEMBL505190 10.46 IC50 0.035 Preclinical
CHEMBL4569923 10.39 Ki 0.041 Preclinical
CHEMBL4439523 10.29 Ki 0.051 Preclinical
CHEMBL502293 10.22 IC50 0.06 Preclinical
CHEMBL4476141 10.15 Ki 0.07 Preclinical
CHEMBL520364 10.15 IC50 0.07 Preclinical
CHEMBL484615 9.9 IC50 0.127 Preclinical
CHEMBL4458743 9.89 Ki 0.13 Preclinical
CHEMBL4588827 9.85 Ki 0.14 Preclinical
Distribution

pChEMBL Value Distribution

198
5.0
217
5.5
137
6.0
67
6.5
29
7.0
19
7.5
34
8.0
40
8.5
56
9.0
14
9.5
pChEMBL
Approved Drugs

Approved Drugs

MELAGATRAN
CHEMBL266349
Approved 2004
Assay Landscape

Assay Landscape

473
Total Assays
1,105
Tested Compounds
3
Assay Types
Binding — 460 assays, 1,105 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 448 1,071 6.0
cell-free format 9 24 5.5
assay format 2 2 6.5
cell-based format 1 8 6.2
ADME — 7 assays, 13 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 6 13 5.2
cell-free format 1 0
Functional — 6 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 6 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine